LINK : William Blair " Overreaction. Reinterates Outperform & $28 target. LINK
Yahoo News - Associated Press 12/17/12 Article Name "Analyst Says Overreaction to Araid Warning Label. You can also copy and paste article title and put into google.
THE ANALYSIS: William Blair's Y. Katherine Xu said in a client note that the market's reaction to the warning label was excessive and has opened up a buying opportunity for investors.
She also believes that the warning label likely won't deter the initial target patients from taking the drug, as they will have failed all other therapies and do not have any other options.
The analyst reaffirmed an "Outperform" rating and $28 price target on the Cambridge, Mass., company.